楚江新材(002171.SZ):擬授權經營層啟動分拆子公司至境內上市的前期籌備
格隆匯 6 月 30日丨楚江新材(002171.SZ)公佈,公司於2020年6月29日召開第五屆董事會第十一次會議,審議通過了《關於授權公司經營層啟動分拆子公司境內上市前期籌備工作的議案》。
根據公司總體戰略安排,為進一步聚焦主業,實現不同業務模塊的均衡發展,推動新技術、新產業、新業態和新模式產業更好地服務科技創新和經濟高質量發展,發揮資本市場優化資源配置,根據中國證券監督管理委員會有關《上市公司分拆所屬子公司境內上市試點若干規定》的政策精神,擬授權公司經營層啟動分拆子公司至境內證券交易所上市的前期籌備。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.